Which analyst expects BiondVax Pharmaceuticals Ltd. (BVXV) to perform well in the near future?

As of close of business last night, BiondVax Pharmaceuticals Ltd.’s stock clocked out at $2.77, up 0.73% from its previous closing price of $2.75. In other words, the price has increased by $+0.0200 from its previous closing price. On the day, 712716 shares were traded. BVXV stock price reached its highest trading level at $3.0000 during the session, while it also had its lowest trading level at $2.6600.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…



To gain a deeper understanding of BVXV’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.80 and its Current Ratio is at 5.80. In the meantime, Its Debt-to-Equity ratio is 6.74 whereas as Long-Term Debt/Eq ratio is at 6.52.

Upgrades & Downgrades

Stock Price History:

Over the past 52 weeks, BVXV has reached a high of $22.90, while it has fallen to a 52-week low of $2.37. The 50-Day Moving Average of the stock is 6.5301, while the 200-Day Moving Average is calculated to be 10.2307.

Shares Statistics:

It appears that BVXV traded 134.56K shares on average per day over the past three months and 717.6k shares per day over the past ten days. A total of 1.87M shares are outstanding, with a floating share count of 1.36M. Insiders hold about 27.75% of the company’s shares, while institutions hold 1.10% stake in the company. Shares short for BVXV as of Oct 13, 2022 were 142.09k with a Short Ratio of 0.02M, compared to 30.78k on Sep 14, 2022.

Earnings Estimates

As of right now, 1 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.01 for the current quarter, with a high estimate of -$0.01 and a low estimate of -$0.01, while EPS last year was -$1.14. The consensus estimate for the next quarter is -$0.01, with high estimates of -$0.01 and low estimates of -$0.01.

Analysts are recommending an EPS of between -$0.02 and -$0.02 for the fiscal current year, implying an average EPS of -$0.02. EPS for the following year is -$0.02, with 1 analysts recommending between -$0.02 and -$0.02.